
    
      PRIMARY OBJECTIVES:

      I. Evaluate patient perceptions surrounding their quality of life (QOL) prior to
      pharmacogenomics (PGx) testing and 3 months post PGx testing.

      II. Understand the clinical utility/relevancy of PGx testing in cancer patients at Mayo
      Clinic Arizona from the viewpoint of their providers.

      OUTLINE:

      Patients undergo one-time collection of saliva sample for pharmacogenomics testing. Patients
      also complete quality of life assessment at baseline and at 3 months after pharmacogenomics
      testing.

      After completion of study, patients are followed for up to 1 year.
    
  